Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Modified Glasgow Prognostic Score (mGPS)

The Modified Glasgow Prognostic Score (mGPS) is an inflammation-based prognostic score used in various cancers, particularly colorectal, lung, and renal cancer.

Evidence-based context for fast calculator use

Purpose:
Modified Glasgow Prognostic Score uses CRP and albumin to assess inflammation-based cancer prognosis and guide supportive care planning.
Population:
patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model
Factors:
C-Reactive Protein, Albumin
Reference:
McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-540.
HomeModified Glasgow Prognostic Score (mGPS)
Pin your most used calculators here by clicking the star in the dropdown.

Modified Glasgow Prognostic Score (mGPS)

mg/L
g/L

Clinical Context & Background

The Modified Glasgow Prognostic Score (mGPS) is an inflammation-based prognostic score used in various cancers, particularly colorectal, lung, and renal cancer. It reflects the host systemic inflammatory response, which is associated with poor survival.
Primary Source EvidenceMcMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-540.
Formula Logic
Based on CRP (>10 mg/L) and Albumin (<35 g/L).

Reference Data

ScoreCriteriaPrognosis
0CRP ≤ 10 mg/LGood Prognosis
1CRP > 10 mg/L AND Albumin ≥ 35 g/LIntermediate Prognosis
2CRP > 10 mg/L AND Albumin < 35 g/LPoor Prognosis

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Modified Glasgow Prognostic Score (mGPS) when modified Glasgow Prognostic Score uses CRP and albumin to assess inflammation-based cancer prognosis and guide supportive care planning.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 through 2.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary site, histology, stage, surgery status, systemic-treatment timing, and disease-specific guideline before applying the result.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer thresholds across colorectal, GIST, gastric, appendiceal, and other peritoneal malignancies.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model

How to apply this result

For a representative case, verify C-Reactive Protein, Albumin, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

GI, GIST & Peritoneal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Fong Clinical Risk Score (CRS)Peritoneal Carcinomatosis Index (PCI)NIH GIST Risk (Miettinen)

Frequently Asked Questions

When should Modified Glasgow Prognostic Score (mGPS) be used?

Use it for patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model when all required inputs and the intended clinical setting are confirmed.

Can Modified Glasgow Prognostic Score (mGPS) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.